Related Experiment Videos
Hepatic angiosarcoma associated with androgenic-anabolic steroids
Lancet (London, England)
|November 24, 1979
Summary
Long-term use of androgenic-anabolic steroids is linked to hepatic angiosarcoma (HAS), representing a fourth known cause. This study highlights environmental agents and steroids as potential triggers for various liver disorders.
Area of Science:
- Hepatology
- Epidemiology
- Toxicology
Background:
- Hepatic angiosarcoma (HAS) is a rare liver cancer.
- Previous studies identified vinyl chloride, Thorotrast, and inorganic arsenic as causes of HAS.
- The role of other environmental agents and medications in HAS etiology remains under investigation.
Observation:
- A retrospective epidemiological study analyzed 168 HAS deaths in the U.S. (1964-1974).
- 37 cases (22%) were linked to known causes: vinyl chloride, Thorotrast, and inorganic arsenic.
- 4 cases (3.1%) of the remaining 131 were associated with androgenic-anabolic steroid use.
Findings:
- Androgenic-anabolic steroid use is proposed as the fourth identified cause of HAS.
- The majority of HAS cases remain of unknown etiology.
- The study links environmental agents and steroids to a spectrum of hepatic disorders.
Implications:
- Long-term androgenic-anabolic steroid use may contribute to HAS development.
- Recognizing precursor liver lesions caused by environmental agents and steroids is crucial.
- Further research is needed to elucidate the mechanisms and identify all etiological factors for HAS.